These results corroborate numerous reports of aberrant SOX gene disruption in various cancer types such as overexpression of SOX2 in lung squamous cell carcinoma [8], low expression of SOX10 in epithelial-derived carcinomas [19], as well as overexpression of SOX4 and SOX11 and underexpression of SOX7 and SOX17 in a variety of cancer types [1, 2, 9, 10, 16-18, 20-54]. This evidence concerns the gene SOX11 and cancer.